Cosmetovigilance studies to assess the safety of cosmetic therapy in hair segments and skin non-laser
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20260431Keywords:
Cosmetovigilance, Platelet-rich plasma, Growth factors, Chemical peelsAbstract
Background: Cosmetic procedures, especially non-laser skin treatments and hair rejuvenation therapies, are increasingly popular, yet ADRs remain a significant safety concern, particularly in patients with comorbidities. This study employed a cosmetovigilance-based approach to evaluate the safety, efficacy, and long-term outcomes of commonly used cosmetic therapies.
Methods: A retrospective interventional cohort study was conducted at Kosmoderma Ltd. involving 410 patients aged 18–60 years who received cosmetic treatments between April and July 2024. Hair rejuvenation therapies included QR678, platelet-rich plasma (PRP), and growth factor concentrate (GFC), while non-laser skin procedures comprised chemical peels and facials. A minimum sample size of 199 was calculated to ensure statistical reliability. ADRs were identified, monitored, and categorized using structured data collection forms. Statistical analyses were performed using Chi-square tests and Spearman correlation to assess associations and risk factors.
Results: Of the 410 patients evaluated, females constituted 78% of the study population, with equal representation of hair and non-laser skin treatments. A statistically significant association was observed between the type of hair therapy and ADR occurrence (χ²=6.89, p=0.032). No significant association was found between non-laser skin treatments and ADRs. Comorbidities, particularly diabetes mellitus, showed a strong association with both the incidence (p<0.001) and severity (p=0.021) of ADRs.
Conclusions: Hair rejuvenation therapies and patient comorbidities significantly influence ADR occurrence. Integration of cosmetovigilance practices and active involvement of clinical pharmacists can enhance patient safety, support informed decision-making, and optimize cosmetic treatment protocols.
Metrics
References
Vigan M, Castelain F. Cosmetovigilance: definition, regulation and use in practice. Eur J Dermatol. 2014;24(6):643-9. DOI: https://doi.org/10.1684/ejd.2014.2493
Toklu HZ, Bülbül A. Pharmacovigilance of cosmetics: a critical review and future perspectives. Curr Drug Saf. 2020;15(3):180-6.
European Parliament and Council. Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products. Off J Eur Union. 2009;L342:59-209.
Sasseville D. Cosmetovigilance: an emerging public health discipline. Dermatitis. 2021;32(1):3-10.
Kumar S, Singh S, Kaur R. Regulatory challenges and safety concerns in the Indian cosmetic market. Indian J Dermatol. 2020;65(6):475-81.
Dhasmana A, Singh P, Bansal P. Heavy metal contamination and microbiological safety of cosmetic products: a public health concern. J Cosmet Dermatol. 2021;20(4):1234-41.
Mehta U, Goyal R, Ghosh S. Underreporting of cosmetic adverse reactions in India: challenges and the need for structured cosmetovigilance. Indian J Pharmacol. 2022;54(2):89-94.
Toklu HZ, Mensah E. Importance of post-marketing surveillance in cosmetovigilance. Ther Adv Drug Saf. 2021;12:1-9.
Vilar S, Friedman C, Hripcsak G. Detection of adverse drug reactions through post-marketing surveillance systems. Clin Pharmacol Ther. 2020;107(1):47-55.
Rudnicka L, Rakowska A, Olszewska M. Hair loss disorders and cosmetic-related adverse reactions. Dermatol Clin. 2021;39(3):361-71.
Rossi A, Anzalone A, Fortuna MC. Safety considerations in hair restoration procedures. J Clin Aesthet Dermatol. 2020;13(6):28-35.
Kaliyadan F, Nambiar A. Injectable peptide-based therapies for androgenetic alopecia: efficacy and safety considerations. J Cosmet Dermatol. 2021;20(10):3046-52.
Alves R, Grimalt R. Platelet-rich plasma therapy for androgenetic alopecia: a systematic review. Dermatol Surg. 2018;44(10):1260-70. DOI: https://doi.org/10.1097/DSS.0000000000001197
Gentile P, Garcovich S. Advances in autologous growth factor therapies for hair loss. Dermatol Ther. 2020;33(6):e14098.
Fabbrocini G, De Padova MP, Tosti A. Non-laser cosmetic procedures: indications, techniques and safety. G Ital Dermatol Venereol. 2020;155(3):289-96.
Alexis AF, Woolery-Lloyd H. Adverse effects of cosmetic dermatologic procedures. Clin Dermatol. 2021;39(4):583-91.
Draelos ZD. Cosmetic facials and skin barrier function. J Clin Aesthet Dermatol. 2020;13(2):38-43.
Soleymani T, Lanoue J, Rahman Z. A practical approach to chemical peels. J Clin Aesthet Dermatol. 2018;11(8):21-8.
Schlessinger J, Schlessinger D. Gender differences in cosmetic procedure utilization. Dermatol Surg. 2020;46(9):1151-7. DOI: https://doi.org/10.1097/DSS.0000000000002184
Callender VD, Wright DR, Davis EC. Sociocultural influences on cosmetic procedure utilization. Clin Dermatol. 2021;39(1):26-33.
Holick MF. Vitamin D deficiency: implications for dermatologic health and procedures. Dermatoendocrinol. 2020;12(1):e1841332.
Ghosh A, Das A, Banerjee S. Impact of metabolic and nutritional disorders on dermatological outcomes. Indian J Dermatol. 2021;66(3):271-7.
Faghihi G, Shahingohar A. Adverse effects of injectable cosmetic therapies: a post-marketing review. J Cosmet Dermatol. 2021;20(9):2685-92.
Sito G, Manzoni V, Sommariva R. Injectable therapies for hair loss: safety comparison in clinical practice. Dermatol Pract Concept. 2020;10(4):e2020089.
Gupta AK, Carviel J. Meta-analysis of platelet-rich plasma safety in dermatology. J Dermatolog Treat. 2021;32(2):197-204.
Gentile P, Scioli MG. Autologous therapies and reduced immunogenicity in regenerative medicine. Stem Cells Transl Med. 2020;9(5):532-41.
Nanda S, Grover C, Reddy BSN. Chemical peels: safety, efficacy and complications. Indian J Dermatol Venereol Leprol. 2020;86(4):399-412. DOI: https://doi.org/10.4103/ijdvl.IJDVL_352_18
Khunger N, Sarkar R. Adverse effects of non-laser aesthetic procedures. J Cutan Aesthet Surg. 2021;14(1):1-10. DOI: https://doi.org/10.4103/JCAS.JCAS_32_17
Boulton AJM. Diabetic complications and impaired wound healing. Lancet Diabetes Endocrinol. 2020;8(9):736-48.
Frykberg RG, Banks J. Challenges in diabetic wound healing. Adv Wound Care. 2021;10(4):199-210.
Inácio P, Cavaco A, Airaksinen M. The role of pharmacists in pharmacovigilance and cosmetovigilance. Pharm Pract (Granada). 2022;20(2):2678.
Downloads
Published
How to Cite
Issue
Section
